SCHEMBL2193229

SCHEMBL2193229

CCOC(=O)c1cc(-c2ccccc2)n(-c2cccc(Cl)c2)n1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 2/20 0.65
LMNA P02545 1/20 0.64
TP53 P04637 1/20 0.64
GABRA2 P47869 1/20 0.62
GABRB2 P47870 1/20 0.62
PPP1CA P62136 1/20 0.61
CHRNA7 P36544 2/20 0.60
FAAH O00519 4/20 0.59
RPA1 P27694 2/20 0.58
MGLL Q99685 2/20 0.55
ALDH1A1 P00352 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.54
GAA P10253 1/20 0.54
KMT2A Q03164 1/20 0.54
BCL2 P10415 1/20 0.54
MDM2 Q00987 1/20 0.54
MCL1 Q07820 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9893959 0.94 LMNA (0.66) CA9LMNATP53GABRA2GABRB2
SCHEMBL1764934 0.94 LMNA (0.59) CA9LMNATP53GABRA2GABRB2
SCHEMBL9630738 0.90 CA9 (0.77) CA9TP53CHRNA7FAAHRPA1
SCHEMBL1765259 0.90 LMNA (0.55) CA9LMNATP53GABRA2GABRB2
SCHEMBL1765509 0.88 CCKAR (0.60) CA9LMNATP53GABRA2GABRB2
SCHEMBL1765252 0.88 LMNA (0.53) CA9LMNATP53GABRA2GABRB2
SCHEMBL1764994 0.88 TP53 (0.55) CA9LMNATP53GABRA2GABRB2
SCHEMBL1764959 0.87 CHRNA7 (0.67) CA9LMNATP53GABRA2GABRB2
SCHEMBL1764908 0.87 FAAH (0.59) CA9LMNATP53GABRA2GABRB2
SCHEMBL2193884 0.87 TP53 (0.52) CA9LMNATP53GABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2278965-B1 SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF AICURIS GMBH & CO KG (DE) 2013-11-13 EP disclosed
US-8314089-B2 Substituted pyrazolamides and their use AICURIS GMBH & CO. KG (DE) 2012-11-20 US disclosed
US-8314089-B2 Substituted pyrazolamides and their use AICURIS GMBH & CO. KG (DE) 2012-11-20 US disclosed
US-20110172207-A1 SUBSTITUTED PYRAZOLAMIDES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-07-14 US disclosed
US-20110172207-A1 SUBSTITUTED PYRAZOLAMIDES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-07-14 US disclosed
US-20110172207-A1 SUBSTITUTED PYRAZOLAMIDES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-07-14 US disclosed
WO-2009115252-A2 SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF AICURIS GMBH & CO. KG (DE) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172207-A1 SUBSTITUTED PYRAZOLAMIDES AND THEIR USE CACNA1A, P2RX4, KCNH1 CA9 1205/4885LMNA 2155/4885TP53 3813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.